U.S. patent application number 09/803572 was filed with the patent office on 2002-01-03 for novel cyclohexene derivatives useful as antagonists of the motilin receptor.
Invention is credited to Chen, Robert H., Xiang, Min A.
Application Number | 20020002192 09/803572 |
Document ID | / |
Family ID | 22694307 |
Filed Date | 2002-01-03 |
United States Patent
Application |
20020002192 |
Kind Code |
A1 |
Chen, Robert H. ; et
al. |
January 3, 2002 |
Novel cyclohexene derivatives useful as antagonists of the motilin
receptor
Abstract
The compounds of formula I are useful in treating
gastrointestinal disorders associated with antagonizing the motilin
receptor. The compounds compete with erythromycin and motilin for
the motilin receptor. In addition the compounds are antagonists of
the contractile smooth muscle response to those ligands.
Inventors: |
Chen, Robert H.; (Belle
Mead, NJ) ; Xiang, Min A; (Bridgewater, NJ) |
Correspondence
Address: |
AUDLEY A. CIAMPORCERO JR.
JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK
NJ
08933-7003
US
|
Family ID: |
22694307 |
Appl. No.: |
09/803572 |
Filed: |
March 9, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60188732 |
Mar 13, 2000 |
|
|
|
Current U.S.
Class: |
514/354 ;
514/448; 514/487; 514/647; 546/316; 549/70; 560/27; 564/336 |
Current CPC
Class: |
C07D 295/088 20130101;
A61P 1/06 20180101 |
Class at
Publication: |
514/354 ;
546/316; 549/70; 560/27; 564/336; 514/448; 514/487; 514/647 |
International
Class: |
A61K 031/455; A61K
031/381; A61K 031/325; A61K 031/135; C07D 333/22; C07D 213/56 |
Claims
What is claimed is:
1. A compound of Formula (I): 9wherein R.sub.1 is selected from
hydrogen, C.sub.1-5alkyl optionally substituted with halogen,
aminoC.sub.1-5alkyl, C.sub.1-5alkylaminoC.sub.1-5alkyl,
di-C.sub.1-5alkylaminoC.sub.1-5alkyl, C.sub.1-5alkylcarbonyl,
C.sub.1-5alkoxycarbonyl, aminocarbonyl,
C.sub.1-9alkylaminocarbonyl, cycloC.sub.3-9alkylaminocarbonyl,
heteroarylaminocarbonyl optionally substituted with one or more
C.sub.1-5alkyl, pyridinylcarbonyl optionally substituted with one
or more substituents selected from the group consisting of halogen
and C.sub.1-5alkyl, thiophenecarbonyl optionally substituted with
one or more substituents selected from the group consisting of
halogen and C.sub.1-5alkyl, phenyl, phenylC.sub.1-5alkyl,
phenoxycarbonyl, phenylcarbonyl, diphenylmethylcarbonyl,
phenylaminocarbonyl, phenylthiocarbonyl, phenylaminothiocarbonyl,
said phenyl, phenylC.sub.1-5alkyl, phenoxycarbonyl, phenylcarbonyl,
diphenylmethylcarbonyl, phenylaminocarbonyl, phenylthiocarbonyl,
phenylaminothiocarbonyl being optionally substituted with one or
more substituents selected from the group consisting of halogen,
C.sub.1-5alkyl, trihalomethyl, C.sub.1-5alkoxy, amino, nitrile,
nitro, C.sub.1-5alkylamino, and di-C.sub.1-5alkylamino, which
substituents may be taken together to form a fused bicyclic
aromatic ring or taken together with the phenyl ring to form a
fused bicyclic 7-10 membered heterocyclic ring having one or two
heteroatoms selected from oxygen, sulfur and nitrogen, and
R.sub.aR.sub.bN-C.sub.1-5alkyl wherein R.sub.a and R.sub.b are
independently selected from hydrogen and C.sub.1-5alkyl, or taken
together to form a morpholine, piperazine, piperidine, or
N-substituted piperidine wherein the N-substitutent is
C.sub.1-5alkyl or phenylC.sub.1-5alkyl; R.sub.2 is selected from
hydrogen, C.sub.1-5alkyl, C.sub.1-5alkoxy, phenyl optionally
substituted with one or more substituents selected from the group
consisting of halogen and C.sub.1-5alkyl, and phenylC.sub.1-5alkyl
optionally substituted with one or more substituents selected from
the group consisting of halogen, C.sub.1-5alkyl, C.sub.1-5alkoxy,
halo and di-C.sub.1-5alkylamino; R.sub.3 is selected from hydrogen,
C.sub.1-5alkylcarbonyl optionally substituted with halogen, and
phenylcarbonyl optionally substituted with one or more substituents
selected from the group consisting of halogen, C.sub.1-5alkyl,
C.sub.1-5alkoxy, amino, C.sub.1-5alkylamino, and
di-C.sub.1-5alkylamino; R.sub.4 is selected from hydrogen,
C.sub.1-5alkyl, C.sub.1-5alkylcarbonyl optionally substituted with
halogen, and phenylcarbonyl optionally substituted with one or more
substituents selected from the group consisting of halogen,
C.sub.1-5alkyl, C.sub.1-5alkoxy, amino, C.sub.1-5alkylamino, and
di-C.sub.1-5alkylamino; n is 0-3; m is 1-5; R.sub.5 is 10wherein: q
is 0-3; t is 0-1; X is oxygen, CH.sub.2, sulfur, hydroxy, thiol, or
NR.sub.C, wherein R.sub.c is selected from hydrogen,
C.sub.1-5alkyl, morpholinoC.sub.1-5alkyl,
piperidinylC.sub.1-5alkyl, N-phenylmethylpiperidinyl, and
piperazinylC.sub.1-5alkyl, with the proviso that if q and t are 0,
X is hydroxy, thiol, or amino, A is C.sub.1-5alkoxycarbonyl,
phenylcarbonyl, or R.sub.7R.sub.8N--wherein R.sub.7 and R.sub.8 are
independently selected from hydrogen, C.sub.1-5alkyl, and
cycloC.sub.1-9alkyl, or R.sub.7 and R.sub.8 form a 5- or 6-membered
heterocyclic ring with one or more heteroatoms selected from the
group consisting of oxygen, nitrogen, sulfur, and sulfoxides and
N-oxides thereof; and R.sub.6 is selected from hydrogen, halogen,
C.sub.1-5alkoxy, C.sub.1-5alkylamino, and di-C.sub.1-5alkylamino;
or a pharmaceutically acceptable salt thereof.
2. A compound of claim 1 wherein R.sub.1 is selected from
phenylaminocarbonyl, substituted phenylaminocarbonyl,
phenylcarbonyl, and substituted phenylcarbonyl; R.sub.2 is
phenylC.sub.1-5alkyl, substituted phenylC.sub.1-5alkyl or phenyl;
R.sub.3 is phenylcarbonyl, substituted phenylcarbonyl, or
substituted C.sub.1-5alkylcarbonyl; R.sub.4 is hydrogen or
C.sub.1-5alkyl; q is 2or 3; A is C.sub.1-5alkoxycarbonyl or
R.sub.7R.sub.8N-- wherein R.sub.7and R.sub.8 are as claimed in
claim 1; t is 1; n is 0; and m is 1.
3. A compound of claim 1, wherein R.sub.1 is phenylaminocarbonyl or
substituted phenylcarbonyl; R.sub.2 is benzyl, 3-Cl benzyl, or
4-methoxybenzyl; R.sub.3 is substituted C.sub.1-5alkylcarbonyl;
R.sub.4 is hydrogen; R.sub.6 is hydrogen; q is 2; A is
R.sub.7R.sub.8N-- wherein R.sub.7 and R.sub.8 taken together form a
5 or 6 membered heterocyclic ring with one or more heteroatoms
selected from the group consisting of oxygen, nitrogen, sulfur, and
N-oxides thereof; and X is oxygen.
4. A compound according to claim 1, wherein R.sub.1 is
phenylaminocarbonyl or halo substituted benzoyl; R.sub.3 is halo
substituted C.sub.1-5alkylcarbonyl; and A is morpolinyl.
5. A compound of claim 1 represented by Formula (Ia). 11wherein Ph
is phenyl.
6. A compound of claim 1 represented by Formula (Ib) 12wherein Ph
is phenyl.
7. A pharmaceutical composition comprising an effective amount of a
compound of claim 1 and a pharmaceutically acceptable carrier.
8. A pharmaceutical composition comprising an effective amount of a
compound of claim 2 and a pharmaceutically acceptable carrier.
9. A pharmaceutical composition comprising an effective amount of a
compound of Formula (Ia) or (Ib), and a pharmaceutically acceptable
carrier. 13
10. A method of treating a condition associated with motilin
receptor activity comprising administering to a subject an
effective amount of a compound of claim 1.
11. A method of claim 10, wherein the condition is irritable bowel
syndrome or esophageal reflux.
12. A method of claim 10, wherein the compound is a compound of
Formula (I) 14wherein R.sub.1 is selected from phenylaminocarbonyl,
substituted phenylaminocarbonyl, phenylcarbonyl, and substituted
phenylcarbonyl; R.sub.2 is phenylC.sub.1-5alkyl, substituted
phenylC.sub.1-5alkyl or phenyl; R.sub.3 is phenylcarbonyl,
substituted phenylcarbonyl, or substituted C.sub.1-5alkylcarbonyl;
R.sub.4 is hydrogen or C.sub.1-5alkyl; q is2or 3; A is
C.sub.1-5alkoxycarbonyl or R.sub.7R.sub.8N-- wherein R.sub.7 and
R.sub.8 are as claimed in claim 1; t is 1; n is 0; and m is 1.
13. A method of claim 10, wherein the compound is a compound of
Formula (I) 15wherein R.sub.1 is phenylaminocarbonyl or substituted
phenylcarbonyl; R.sub.2 is benzyl, 3-Cl benzyl, or 4-methoxybenzyl;
R.sub.3 is substituted C.sub.1-5alkylcarbonyl; R.sub.4 is hydrogen;
R.sub.6 is hydrogen; q is 2; A is R.sub.7R.sub.8N-- wherein R.sub.7
and R.sub.8 taken together form a 5 or 6 membered heterocyclic ring
with one or more heteroatoms selected from the group consisting of
oxygen, nitrogen, sulfur, and N-oxides thereof; and X is
oxygen.
14. A method of claim 10, wherein the compound is a compound of
Formula (Ia) or (Ib). 16
15. A method of treating a gastrointestinal side effect resulting
from administration of erythromycin, which comprises administering
to a subject an effective amount of a compound of claim 1.
16. A method of claim 15, wherein the condition is irritable bowel
syndrome or esophageal reflux.
17. A method of claim 15, wherein the compound is a compound of
Formula (I) 17wherein R.sub.1 is selected from phenylaminocarbonyl,
substituted phenylaminocarbonyl, phenylcarbonyl, and substituted
phenylcarbonyl; R.sub.2 is phenylC.sub.1-5alkyl, substituted
phenylC.sub.1-5alkyl or phenyl; R.sub.3 is phenylcarbonyl,
substituted phenylcarbonyl, or substituted C.sub.1-5alkylcarbonyl;
R.sub.4 is hydrogen or C.sub.1-5alkyl; q is 2 or 3; A is
C.sub.1-5alkoxycarbonyl or R.sub.7R.sub.8N-- wherein R.sub.7 and
R.sub.8 are as claimed in claim 1; t is 1; n is 0; and m is 1.
18. A method of claim 15, wherein the compound is a compound of
Formula (I) 18wherein R.sub.1 is phenylaminocarbonyl or substituted
phenylcarbonyl; R.sub.2 is benzyl, 3-Cl benzyl, or 4-methoxybenzyl;
R.sub.3 is substituted C.sub.1-5alkylcarbonyl; R.sub.4 is hydrogen;
R.sub.6 is hydrogen; q is 2; A is R.sub.7R.sub.8N-- wherein R.sub.7
and R.sub.8 taken together form a 5 or 6 membered heterocyclic ring
with one or more heteroatoms selected from the group consisting of
oxygen, nitrogen, sulfur, and N-oxides thereof; and X is
oxygen.
19. A method of claim 15, wherein the compound is a compound of
Formula (Ia) or (Ib). 19
Description
FIELD OF THE INVENTION
[0001] This invention relates to a series of novel cyclohexene
derivatives, pharmaceutical compositions containing them and
intermediates used in their manufacture. The compounds of the
invention are useful as non-peptidyl antagonists of the motilin
receptor.
BACKGROUND
[0002] In mammals, the digestion of nutrients and the elimination
of waste is controlled by the gastrointestinal system. This system
is, to say the least, complicated. There are a number of natural
peptides, ligands, enzymes, and receptors which play a vital role
in this system and are potential targets for drug discovery.
Modifying the production of, or responses to these endogenous
substances can have an effect upon the physiological responses such
as diarrhea, nausea, and abdominal cramping. One example of an
endogenous substance which affects the gastrointestinal system is
motilin.
[0003] Motilin is a peptide of 22 amino acids which is produced in
the gastrointestinal system of a number of species. Although the
sequence of the peptide varies from species to species, there are a
great deal of similarities. For example, human motilin and porcine
motilin are identical; while motilin isolated from the dog and the
rabbit differ by five and four amino acids, respectively. Motilin
induces smooth muscle contractions in the stomach tissue of dogs,
rabbits, and humans as well as in the colon of rabbits. Apart from
local gastrointestinal intestinal tissues, motilin and its
receptors have been found in other tissues. For example, motilin
has been found in circulating plasma, where a rise in the
concentration of motilin has been associated with gastric effects
which occur during fasting in dogs and humans (Itoh, Z. et al.,
1976, Scand. J. Gastroenterol. 11:93-110; Vantrappen, G. et al.,
1979, Dig. Dis Sci 24, 497-500). In addition, when motilin was
intravenously administered to humans it was found to increase
gastric emptying and gut hormone release (Christofides, N. D. et
al., 1979, Gastroenterology 76:903-907).
[0004] Aside from motilin itself, there are other substances which
are agonists of the motilin receptor and which elicit
gastrointestinal emptying. One of those agents is the antibiotic
erythromycin. Even though erythromycin is a useful drug, a great
number of patients are affected by the drug's gastrointestinal side
effects. Studies have shown that erythromycin elicits biological
responses that are comparable to motilin itself and therefore may
be useful in the treatment of diseases such as chronic idiopathic
intestinal pseudo-obstruction and gastroparesis (Weber, F. et al.,
1993, The American Journal of Gastroenterology, 88:4, 485-90).
[0005] Although motilin and erythromycin are agonists of the
motilin receptor, there is a need for antagonists of this receptor
as well. The nausea, abdominal cramping, and diarrhea which are
associated with motilin agonsits are not always welcome
physiological events. The increased gut motility induced by motilin
has been implicated in diseases such as Irritable Bowel Syndrome
and esophageal reflux. Therefore researchers have been searching
for motilin antagonists.
[0006] One such antagonist is OHM-11526. This is a peptide derived
from porcine motilin which competes with both motilin and
erythromycin for the motilin receptor in a number of species,
including rabbits and humans. In addition, this peptide is an
antagonist of the contractile smooth muscle response to both
erythromycin and motilin in an in vitro rabbit model (Depoortere,
I. et al., 1995, European Journal of Pharmacology, 286,
241-47).
[0007] Although this substance is potent in that model, it is a
peptide and as such it is susceptible to the enzymes of the
digestive tract (Zen Itoh, Motilin, xvi, 1990). Therefore it is
desirable to find other agents which are not peptides as potential
motilin antagonists. The compounds of this invention are such
agents.
[0008] U.S. Pat. No. 5,972,939 to Chen et al. describes
cyclopentene derivatives which are useful in treating
gastrointestinal disorders associated with antagonizing the motilin
receptor.
SUMMARY OF THE INVENTION
[0009] The present invention is directed to compounds of Formula I
1
[0010] wherein
[0011] R.sub.1 is selected from hydrogen, C.sub.1-5alkyl optionally
substituted with halogen, aminoC.sub.1-5alkyl,
C.sub.1-5alkylaminoC.sub.1- -5alkyl,
di-C.sub.1-5alkylaminoC.sub.1-5alkyl, C.sub.1-5alkylcarbonyl,
C.sub.1-5alkoxycarbonyl, aminocarbonyl,
C.sub.1-9alkylaminocarbonyl, cycloC.sub.3-9alkylaminocarbonyl,
heteroarylaminocarbonyl optionally substituted with one or more
C.sub.1-5alkyl, pyridinylcarbonyl optionally substituted with one
or more substituents selected from the group consisting of halogen
and C.sub.1-5alkyl, thiophenecarbonyl optionally substituted with
one or more substituents selected from the group consisting of
halogen and C.sub.1-5alkyl, phenyl, phenylC.sub.1-5alkyl,
phenoxycarbonyl, phenylcarbonyl, diphenylmethylcarbonyl,
phenylaminocarbonyl, phenylthiocarbonyl, phenylaminothiocarbonyl,
said phenyl, phenylC.sub.1-5alkyl, phenoxycarbonyl, phenylcarbonyl,
diphenylmethylcarbonyl, phenylaminocarbonyl, phenylthiocarbonyl,
phenylaminothiocarbonyl being optionally substituted with one or
more substituents selected from the group consisting of halogen,
C.sub.1-5alkyl, trihalomethyl, C.sub.1-5alkoxy, amino, nitrile,
nitro, C.sub.1-5alkylamino, and di-C.sub.1-5alkylamino, which
substituents may be taken together to form a fused bicyclic
aromatic ring or taken together with the phenyl ring to form a
fused bicyclic 7-10 membered heterocyclic ring having one or two
heteroatoms selected from oxygen, sulfur and nitrogen, and
R.sub.aR.sub.bN-C.sub.1-5alkyl wherein R.sub.a and R.sub.b are
independently selected from hydrogen and C.sub.1-5alkyl, or taken
together to form a morpholine, piperazine, piperidine, or
N-substituted piperidine wherein the N-substitutent is
C.sub.1-5alkyl or phenylC.sub.1-5alkyl;
[0012] R.sub.2 is selected from hydrogen, C.sub.1-5alkyl,
C.sub.1-5alkoxy, phenyl optionally substituted with one or more
substituents selected from the group consisting of halogen and
C.sub.1-5alkyl, and phenylC.sub.1-5alkyl optionally substituted
with one or more substituents selected from the group consisting of
halogen, C.sub.1-5alkyl, C.sub.1-5alkoxy, halo and
di-C.sub.1-5alkylamino;
[0013] R.sub.3 is selected from hydrogen, C.sub.1-5alkylcarbonyl
optionally substituted with halogen, and phenylcarbonyl optionally
substituted with one or more substituents selected from the group
consisting of halogen, C.sub.1-5alkyl, C.sub.1-5alkoxy, amino,
C.sub.1-5alkylamino, and di-C.sub.1-5alkylamino;
[0014] R.sub.4 is selected from hydrogen, C.sub.1-5alkyl,
C.sub.1-5alkylcarbonyl optionally substituted with halogen, and
phenylcarbonyl optionally substituted with one or more substituents
selected from the group consisting of halogen, C.sub.1-5alkyl,
C.sub.1-5alkoxy, amino, C.sub.1-5alkylamino, and
di-C.sub.1-5alkylamino;
[0015] n is 0-3;
[0016] m is 1-5;
[0017] R.sub.5 is 2
[0018] wherein:
[0019] q is 0-3;
[0020] t is 0-1;
[0021] X is oxygen, CH.sub.2, sulfur, hydroxy, thiol, or NR.sub.c,
wherein
[0022] R.sub.c is selected from hydrogen, C.sub.1-5alkyl,
morpholinoC.sub.1-5alkyl, piperidinylC.sub.1-5alkyl,
N-phenylmethylpiperidinyl, and piperazinylC.sub.1-5alkyl,
[0023] with the proviso that if q and t are O, X is hydroxy, thiol,
or amino,
[0024] A is C.sub.1-5alkoxycarbonyl, phenylcarbonyl, or
R.sub.7R.sub.8N--
[0025] wherein R.sub.7 and R.sub.8 are independently selected from
hydrogen, C.sub.1-5alkyl, and cycloC.sub.1-9alkyl, or R.sub.7 and
R.sub.8 form a 5- or 6-membered heterocyclic ring with one or more
heteroatoms selected from the group consisting of oxygen, nitrogen,
sulfur, and sulfoxides and N-oxides thereof; and
[0026] R.sub.6 is selected from hydrogen, halogen, C.sub.1-5alkoxy,
C.sub.1-5alkylamino, and di-C.sub.1-5alkylamino;
[0027] or a pharmaceutically acceptable salt thereof.
[0028] The compounds of Formula I are useful in treating
gastrointestinal disorders associated with the motilin receptor.
The compounds compete with erythromycin and motilin for the motilin
receptor. In addition, the compounds are antagonists of the
contractile smooth muscle response to those ligands.
[0029] The present invention also comprises pharmaceutical
compositions containing one or more of the compounds of Formula I
as well as methods for the treatment of disorders related to the
gastrointestinal system which are associated with the motilin
receptor. Such diseases include Irritable Bowel Syndrome,
esophageal reflux, and the gastrointestinal side effects of
erythromycin.
DETAILED DESCRIPTION OF THE INVENTION
[0030] The terms used in describing the invention are commonly used
and known to those skilled in the art. However, the terms that
could have other meanings are defined. "Independently" means that
when there are more than one substituent, the substituents may be
different. The term "alkyl" refers to straight, cyclic and
branched-chain alkyl groups and "alkoxy" refers 0-alkyl where alkyl
is as defined supra. "Halogen" or "halo" means F, Cl, Br, and I.
The symbol "Ph" refers to phenyl. The term "fused bicyclic
aromatic" includes fused aromatic rings such as naphthyl and the
like. The term "fused bicyclic heterocycle" includes benzodioxoles
and the like. The term "heteroaryl" as used herein represents a
stable five or six membered monocyclic aromatic ring system which
consists of carbon atoms and from one to three heteroatoms selected
from N, O, or S. The heteroaryl group may be attached at any
heteroatom or carbon atom which results in the creation of a stable
structure. Examples of heteroaryl groups include, but are not
limited to, triazole, thiazole, thiadiazole, oxazole, imidazole,
pyrazole, pyrimidine, isothiazole, isoindole, isoxazole and the
like. The heteroaryl group may be further substituted with one or
more groups such as alkyl, substituted alkyl, and halogen. More
particularly, the heteroaryl group may be substituted with
methyl.
[0031] The term "subject" as used herein, refers to an animal,
preferably a mammal, most preferably a human, who has been the
object of treatment, observation or experiment.
[0032] Since the compounds of the invention have a chiral center,
they may be prepared as a single stereoisomer or in racemic form as
a mixture of some possible stereoisomers. The non-racemic forms may
be obtained by either synthesis or resolution. The compounds may,
for example, be resolved into their components enantiomers by
standard techniques, such as the formation of diastereomeric pairs
by salt formation. The compounds may also be resolved by covalent
linkage to a chiral auxiliary, followed by chromatographic
separation and/or crystallographic separation, and removal of the
chiral auxiliary. Alternatively, the compounds may be resolved
using chiral chromatography.
[0033] When compounds contain a basic moiety, acid addition salts
may be prepared and may be chosen from hydrochloric, hydrobromic,
hydroiodic, perchloric, sulfuric, nitric, phosphoric, acetic,
propionic, glycolic, lactic, pyruvic, oxalic, malonic, succinic,
maleic, fumaric, malic, tartaric, citric, benzoic, cinnamic,
mandelic, methanesulfonic, p-toluenesulfonic, cyclohexanesulfamic,
salicylic, 2-phenoxybenzoic, 2-acetoxybenzoic, saccharin, and the
like. Such salts can be made by reacting the free base of compounds
of formula I with the acid and isolating the salt.
[0034] Compounds of the present invention may be prepared by known
methods such as those disclosed in U.S. Pat. No. 5,972,939 to Chen
et al., which is hereby incorporated by reference in its
entirety.
[0035] The compounds of the invention may be prepared by the
following procedures, where some schemes produce more than one
embodiment of the invention. In those cases, the choice of scheme
is a matter of discretion which is within the capabilities of those
skilled in the art.
[0036] Essentially, Scheme 1 assembles two halves of the molecule
and couples them. For one half, 3-ethoxy-2-cylclohepten-1 -one, 1a
(a known compound), may be the starting material. 1a may be treated
with a Grignard reagent, 1b such as 4-fluorobenzyl magnesium
bromide (a known compound) preferably at room temperature (rt)
under an inert atmosphere, using ether as a solvent to give the
.alpha.,.beta.-unsaturated ketone derivative 1c. Treatment of 1c
with a reducing agent such as lithium aluminum hydride (LAH)
preferably at 0.degree. C. to room temperature will give the
alcohol, Id. This alcohol may be treated with a strong base such as
NaH and trichloroacetonitrile preferably from 0.degree. C. to room
temperature to give the amide 1e. This seven-membered ring amide
may be sequentially treated on dry ice with ozone, dimethylsulfide,
and a catalytic amount of acid such as toluene sulfonic acid. Once
addition is complete, the mixture can be warmed to room temperature
over to give the six membered ring aldehyde, 1f, as a racemic
mixture.
[0037] To assemble the other half, an aromatic alcohol 1 g, such as
3-hydroxyaniline may be treated with a mild base, such as
K.sub.2CO.sub.3, in a suitable solvent such as ethanol (EtOH) at
reflux. This mixture may be subsequently treated with a halide
derivative 1h, such as 3-chloropropylmorpholine preferably at room
temperature to give the amine 1i. This amine may be treated with
the aldehyde 1f and NaCNBH.sub.3 in methanol (MeOH) preferably at
room temperature to give a compound of the invention Ic, as a
racemic mixture.
[0038] If pure enantiomers are desired, they may be obtained in any
of three stages of the synthesis. The alcohol 1d, the aldehyde 1f,
and the product Ic may all be separated via HPLC using chiral
columns or methods well known in the art. With respect to all three
compounds, they may be further manipulated to give other compounds
of the invention without sacrificing their enantiomeric purity.
[0039] Scheme 1 may be used to produce other compounds of the
invention. For example, to produce compounds where X is sulfur,
simply replace reagent 1h with an aromatic thiol, such as
3-aminothiophenol and carry out the remaining steps of the Scheme.
3
[0040] To produce other substitutions at R.sub.3 or R.sub.4, some
of the products of Scheme 1 may be used as shown in Scheme 2. For
example, to produce a compound where R.sub.3 is hydrogen and
R.sub.4 is CH.sub.3C(O)--, the seven-membered ring intermediate 1e
may be treated with a base, such as barium hydroxide, at reflux in
ethanol (EtOH) to give the free amine 2a. The amine may be
subsequently treated with an acid anhydride, such as
trifluoroacetic anhydride to give 2b. This intermediate may be
carried through the remaining steps of Scheme 1 to produce the
desired compound Id. 4
[0041] The products of Scheme 1 may be used to produce other
compounds of the invention as shown in Scheme 3. For example, to
produce compounds of type Ie, compound Ic may be treated with a
phenyl isocyanate preferably at room temperature. To produce
compounds of type If, Ic may be treated preferably at room
temperature with acid chloride derivatives such as benzoyl
chloride. In order to produce thiols Iq, compounds of type Ic may
be treated with isothiocyanates, such as phenylisothiocyanate
preferably at room temperature. As discussed earlier, if pure
enantiomers are desired, they may be obtained by chromatography of
the reactant Ic or the products. 5
[0042] Scheme 4 makes use of the intermediate of Scheme 1.
Treatment of the aldehyde, 1f, with a nitroaniline derivative 4a (a
known compound), and NaCNBH.sub.3 preferably at room temperature
gives the coupled intermediate 4b. This intermediate may be
acylated with benzoyl chloride and a mild base such as
triethylamine to give the N-acyl intermediate 4c. 4c may be treated
with a reducing agent such as Pd/C to give the aniline compound Ih.
This compound may be coupled with a halogen derivative 4d, such as
3-chloropropylpiperidine, using 1,8. Diazabieyclo (5,4,0)
undec-7-ene (DBU) and an alcoholic solvent at reflux to give a
mixture of mono- and di-amine products (Ii and Ij). 6
[0043] To prepare compounds of the invention where n is 1-3,
products of Scheme 1 may be used as shown in Scheme 5. Intermediate
1f may be treated with 3-(m-hydroxyphenyl)propylamine, an aromatic
amino alcohol derivative 5a known in the art, and NaCNBH.sub.3
preferably at room temperature to give the amine Ik. Treatment of
Ik with a thiocyanate derivative 5b, and a mild base preferably at
room temperature gives the substituted thioamide Im. This compound
may be treated with a halide reagent, 5c, and a base such as DBU in
an alcoholic solvent at reflux to give the O-substituted compound
of the invention In. 7
[0044] To produce compounds of the invention wherein R.sub.7 and
R.sub.8 form sulfoxide or N-oxide, the procedure of Scheme 6 may be
followed (MCPBA refers to 3-chloroperoxybenzoic acid). 8
[0045] Radiolabeled Motilin
[0046] The compounds of the invention were tested for their ability
to compete with radiolabeled motilin (porcine) for the motilin
receptors located on the colon of mature rabbits. The colon from
mature New Zealand rabbits was removed, dissected free from the
mucosa and serosa layers, and diced into small pieces. The muscle
tissues were homogenized in 10 volumes of buffer (50 mM Tris-Cl, 10
mM MgCl.sub.2, 0.1 mg/mL bactracin, and 0.25 mM Peflabloc, pH 7.5)
in a Polytron (29,000 rpm, 4.times.15 seconds). The homogenate was
centrifuged at 1000.times.g for 15 min. and the supernatant
discarded. The pellet was washed twice before being suspended in
homogenizing buffer. This crude homogenate was then passed first
through a 19 gauge needle then a 23 gauge needle to further suspend
the material and stored at -80.degree. C. In a total volume of 0.50
mL, the binding assay contained the following components added
sequentially: buffer (50 mM Tris-Cl, 10 mM MgCl.sub.2, 1 mM EDTA,
15 mg/mL BSA, 5 .mu.g/mL leupeptin, aprotinin, and pepstatin, and
0.1 mg/mL, bactracin), I.sup.125 motilin (Amersham, ca
50,000-70,000 cpm, 25-40 pM), the test compound (the initial
concentration was 2 mM/100% DMSO, which was diluted with H.sub.2O
to a final concentration of 10 .mu.M) and membrane protein (100-300
.mu.g). After 30 min at 30.degree. C., the material was cooled on
ice and centrifuged at 13,000.times.g for 1 minute. The pellet was
washed with 1 mL 0.9% saline and centrifuged at 13,000.times.g for
15 seconds. The pellet was washed again with cold saline and the
supernatant was removed. The pellet was counted in the gamma
counter to determine the percentage of unbound motilin and thereby
the percent inhibition of the test compound.
[0047] % inhibition was determined for some compounds by standard
techniques:
[0048] 3-Benzyl-3-trichloroacetamido-1-( N-phenylaminocarbonyl
)-N-[(3-(2-morpholinoethoxy)phenyl)amino]methylcyclohexene (Example
6): 62% @ 50 nM;
[0049]
3-Benzyl-3-trichloroacetamido-1-N[(3-(2-morpholinoethoxy)phenyl)ami-
no]methylcyclohexene (Example 7): 59% @ 50 nM.
[0050] Rabbit duo denum Smooth Muscle
[0051] Compounds of the invention may be evaluated for their
ability to inhibit motilin and erythromycin induced contractions in
the rabbit duodenum smooth muscle. Rabbits may be fasted 24-48 h
and euthanized. The venral midline incision may be made
approximately 7.5 cm above the umbilicus up to the xyphoid process,
exposing the upper peritoneal cavity. The first 8 cm of the
duodenum starting at the pyloric valve may be quickly removed and
placed in Krebs solution containing NaCl (120 mM), KCl (4.7 mM),
MgSO.sub.4*7 H.sub.2O (1.2 mM), CaCl.sub.2*2 H.sub.2O (2.4 mM),
KH.sub.2PO.sub.4 (1 mM), D-glucose (10 mM), and NaHCO.sub.3 (24
mM). The lumen may be flushed with Krebs solution and excess tissue
removed. The tissue may be cut lengthwise, splayed open with the
longitudinal muscle layer facing up, and the longitudinal muscle
layer released away from the circular muscle and cut into
3.times.30 mm strips. A pre-tied 4-0 silk ligature with a loop may
be placed at the middle of the strip and the strip folded over the
loop so the strip is half its original length. The tissues may be
mounted in a 10 mL tissue bath (Radnotti Glass Technology, Inc.,
Monrovia, Calif.) containing Krebs solution gassed with 95%
O.sub.2+5% CO.sub.2 at 37.degree. C. The tissues may be attached to
a force displacement transducer (FT03, Grass Instruments, Quincy,
Mass.) and resting tension slowly increased to 1 g. The tissues may
be allowed to equilibrate for 60-90 min with 2-3 wash cycles. The
tissues may be equilibrated with two initial contractions induced
by a concentration of acetylcholine (1.times.10.sup.-4 M) that
produces a maximal contraction (0.1 mM), with the highest taken as
100% maximal contraction of that tissue. Base line and response
levels may be expressed as grams tension developed and as a percent
of the response to acetylcholine. The test compounds may be
dissolved in DMSO (2 mM/I 100% DMSO) and applied to the prepared
strips 5-15 minutes prior to the addition of porcine motilin. After
addition, the tension is constantly monitored over 5 min and the
maximum tension is recorded. The percent contraction may be
measured at four ascending concentrations and where appropriate
IC.sub.50's may be determined.
[0052] The preferred compounds are those wherein:
[0053] R.sub.1 is selected from phenylaminocarbonyl, substituted
phenylaminocarbonyl, phenylcarbonyl, and substituted
phenylcarbonyl;
[0054] R.sub.2 is phenylC.sub.1-5alkyl, substituted
phenylC.sub.1-5alkyl or phenyl;
[0055] R.sub.3 is phenylcarbonyl, substituted phenylcarbonyl, or
substituted C.sub.1-5alkylcarbonyl;
[0056] R.sub.4 is hydrogen or C.sub.1-5alkyl;
[0057] q is2or 3;
[0058] A is C.sub.1-5alkoxycarbonyl or R.sub.7R.sub.8N-- wherein
R.sub.7 and R.sub.8 are as described above;
[0059] t is1;
[0060] n is O; and
[0061] m is 1.
[0062] In another preferred embodiment of the invention:
[0063] R.sub.1 is phenylaminocarbonyl or substituted
phenylcarbonyl;
[0064] R.sub.2 is benzyl, 3-Cl benzyl, or 4-methoxybenzyl;
[0065] R.sub.3 is substituted C.sub.1-5alkylcarbonyl;
[0066] R.sub.4 is hydrogen;
[0067] R.sub.6 is hydrogen;
[0068] q is 2;
[0069] A is R.sub.7R.sub.8N-- wherein R.sub.7 and R.sub.8 taken
together form a 5 or 6 membered heterocyclic ring with one or more
heteroatoms selected from the group consisting of oxygen, nitrogen,
sulfur, and N-oxides thereof; and
[0070] X is oxygen.
[0071] Also illustrative of the present invention is the compound
of Formula I wherein:
[0072] R.sub.1 is phenylaminocarbonyl or halo substituted
benzoyl;
[0073] R.sub.3 is halo substituted C.sub.1-5alkylcarbonyl; and
[0074] A is morpolinyl.
[0075] To prepare the pharmaceutical compositions of this
invention, one or more compounds or salts thereof, as the active
ingredient, is intimately admixed with a pharmaceutical carrier
according to conventional pharmaceutical compounding techniques,
which carrier may take a wide variety of forms depending on the
form of preparation desired for administration, e.g., oral or
parenteral. In preparing the compositions in oral dosage form, any
of the usual pharmaceutical media may be employed. Thus for liquid
oral preparations, such as for example, suspensions, elixirs and
solutions, suitable carriers and additives include water, glycols,
oils, alcohols, flavoring agents, preservatives, coloring agents
and the like; for solid oral preparations such as, for example,
powders, capsules and tablets, suitable carriers and additives
include starches, sugars, diluents, granulating agents, lubricants,
binders, disintegrating agents and the like. Because of their ease
in administration, tablets and capsules represent the most
advantageous oral dosage form, in which case solid pharmaceutical
carriers are obviously employed. If desired, tablets may be sugar
coated or enteric coated by standard techniques. For parenterals,
the carrier will usually comprise sterile water, though other
ingredients, for example, for purposes such as aiding solubility or
for preservation, may be included. Injectable suspensions may also
be prepared, in which case appropriate liquid carriers, suspending
agents and the like may be employed. The pharmaceutical
compositions herein will preferably contain per dosage unit, e.g.,
tablet, capsule, powder, injection, teaspoonful and the like, from
about 5 to about 500 mg of the active ingredient, although other
unit dosages may be employed.
[0076] In therapeutic use for treating disorders of the
gastrointestinal system in mammals, the compounds of this invention
may be administered in an amount of from about 0.5 to 100 mg/kg 1-2
times per day orally. In addition, the compounds may be
administered via injection at 0.1-10 mg/kg per day. Determination
of optimum dosages for a particular situation is within the
capabilities of formulators.
[0077] In order to illustrate the invention, the following examples
are included. These examples do not limit the invention. They are
meant to illustrate and suggest a method of practicing the
invention. Although there are other methods of practicing this
invention, those methods are deemed to be within the scope of this
invention.
EXAMPLES
Example 1
3-Benzyl-2-cyclohepten-1-one
[0078] A solution of 3-ethoxy-2-cyclohepten-1-one(5 g, 0.89 mol) in
THF (70 mL) was added at room temperature to a solution of 2M
benzyl magnesium chloride (800 ml) under N.sub.2 and stirred for 6
h. The resulting mixture was poured into a solution of 30%
H.sub.2SO.sub.4 and stirred for 5 h. The resulting organic layer
was separated, and the aqueous layer was extracted with several
portions of ether. The combined organic layer was dried
(MgSO.sub.4), and concentrated in vacuo to give
3-benzyl-2-cyclohepten-1-one (3.1 g, 65%) as a colorless oil. NMR
(CDCl3); 3.45(s,2H.sub.1benzylic protons), 5.97 (bs, 1H, olefinic
proton), 7.22 (m, 5H, aromatic protons).
Example 2
3-Benzyl-2-cyclohepten-1-ol
[0079] A solution of 3-benzyl-2-cyclohepten-1-one (3.1 g, 18 mmol)
in either 100 mL) was slowly added to a suspension of lithium
aluminum hydride (LAH) (684 mg, 0.87 mol) and ether (100 mL) at
0.degree. C. under N.sub.2. The resulting mixture was stirred
overnight at ambient temperature and cooled to 0.degree. C.
Saturated K.sub.2CO3 solution was added to quench the excess LAH,
the mixture was filtered through Celite and washed with several
portions of ether. The combined organic layers were dried
(MgSO.sub.4) and concentrated in vacuo to give the title compound
(3 g, 93%) as a colorless oil. NMR (CDCl3):3.32(ABq,J=6 Hz,2H,
benzylic protons), 4.42 (bs, 1H, CHOH), 5.58 (bs, 1H, olefinic
proton), 7.22 (m, 5H, aromatic protons).
Example 3
3-Benzyl-3-trichloroacetamidocyclopheptene
[0080] A solution of 3-benzyl-2-cycloheptene-1-ol (1.1 g, 5.45
mmol) in ether (50 mL) was added to a suspension of hexane washed
60% NaH (230 mg, 5.75 mol) in ether (5 mL) at 0.degree. C. under
N.sub.2 and stirred for 1 h. Trichloroacetonitrile (0.8 g, 5.54
mmol) was slowly added and the resulting mixture was allowed to
warm to ambient temperature and stirred overnight. The solvent was
removed in vacuo, hexane (25 mL) was added and the mixture was
cooled to 0.degree. C. Methanol (1 mL) was added and the resulting
solid was filtered through Celite. The organic solvent was removed
in vacuo to give a crude intermediate. This intermediate was
dissolved in xylene (75 mL) and heated to reflux for 3 h under
N.sub.2. The solvent was removed in vacuo, and the residue was
purified by column on silica gel (100 g, ethylacetate
(EtOAc)/hexane (1:9)) to give the title compound (207 mg, 11%) as a
white crystal. MS (MH.sup.+=346).
Example 4
3-Benzyl-3-trichloroacetamido-2-cyclohexenecarboxaldehyde
[0081] A solution of 3-benzyl-3-trichloroacetamidocycloheptene (207
mg, 0.60 mmol) in methylene chloride (80 mL) was treated with ozone
at -78.degree. C. until the solution turned blue. The excess of
ozone was removed with a stream of N.sub.2, dimethyl sulfide (0.2
mL) was added and the mixture was allowed to warm to room
temperature paratoluene sulfonic acid-monohydrate (TsOH--H.sub.2O)
(20 mg) was added and the resulting mixture was stirred for three
days. The resulting mixture was treated with 1N NaOH (20 mL). The
organic layer was separated and the aqueous layer was extracted
with methylene chloride (2.times.15 mL). The combined organic layer
was dried and the solvent was removed in vacuo. The residue was
purified by column on silica gel. gel (EtOAc/hexane (1:9.about.2:9)
to give the aldehyde (63 mg, 30%) as a thick brown oil (crude
product), which was carried to Example 5 as its starting
material.
Example 5
3-Benzyl-3-trichloroacetamido-1-N-[(3-(2-morpholinoethoxy)phenyl)amino]met-
hylcyclohexene
[0082] NaCNBH.sub.4 (23 mg, 0.61 mM.) was added to a solution of
3-benzyl-3-trichloroacetamido-2-cyclohexenecarboxaldehyde (63 mg,
0.17 mmol), 3-(2-morpholinoethoxy) aniline (130 mg, 0.59 mmol)
acetic acid (0.05 mL) in methanol (10 mL) at room temperature under
N.sub.2 and stirred for 30 min. Most of methanol was removed in
vacuo and the residue was diluted with methylene chloride, washed
with 1N. NaOH and dried. The solvent was removed in vacuo and
residue was purified by column chromatography on silica gel using
hexane:ethyl acetate (1:9) to give the title compound (58 mg, 60%)
a a light brown oil. MS (MH.sup.+=566).
Example 6
3-Benzyl-3-trichloroacetamido-1-(
N-phenylaminocarbonyl)-N-[(3-(2-morpholi-
noethoxy)phenyl)amino]methylcyclohexene
[0083] A solution of
3-benzyl-3-trichloroacetamido-1-N[(3-(2-morpholinoeth-
oxy)phenyl)amino]methylcyclohexene (28 mg, 0.05 mM), phenyl
isocyanate (59 mg, 0.49 mM) and triethyl amine (100 mg) in
methylene chloride (5 mL) was stirred at room temperature for 16
hours. Most of solvent was removed in vacuo and the residue was
purified by preparative TLC to give
3-Benzyl-3-trichloroacetylamino-1-(N-phenylcarbonyl)-N-[(3-(2-morpholinoe-
thyl)phenyl)amino]methylcyclohexene as a thick oil (21 mg). MS
(MH.sup.+=685). This was converted to the mono-hydrochloride salt
mp 103-105 (dec).
Example 7
3-Benzyl-3-trichloroacetamido-1-N[(3-(2-morpholinoethoxy)phenyl)amino]meth-
ylcyclohexene
[0084] 3,4-Difluorobenzoyl chloride (31 mg, 0.18 mM) was added to a
solution of
3-benzyl-3-trichloroacetamido-1-N[(3-(2-morpholinoethoxy)phen-
yl)amino]methylcyclohexene (26 mg, 0.05 mM) and triethylamine (0.2
mL) in methylene chloride (3 mL) at room temperature under N.sub.2
and stirred for 2 hours. Most of solvent was removed in vacuo and
the oily residue was purified by preparative TLC to give the title
compound as a thick oil (22 mg, 58%). MS (MH.sup.+=706). This was
converted to the mono-hydrochloride salt mp 103-105 (dec).
* * * * *